Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Lateral Flow Assay Enhanced for Multiplex Detection

By LabMedica International staff writers
Posted on 20 Mar 2013
Lateral flow assays (LFAs) are popular point-of-care diagnostic tools because they are rapid and easy to use. More...
However, LFAs often lack analytical sensitivity and quantitative output and may be difficult to multiplex, limiting their usefulness in biomarker measurement.

Scientists at SRI International (Menlo Park, CA, USA) designed a quantitative, multiplex LFA with readily available near-infrared (NIR) detection to improve analytical sensitivity. They constructed and optimized a multiplex LFA that simultaneously and accurately measured interleukin (IL)-6 and C- reactive protein (CRP) in 10% human plasma on one test strip.


Commercially available antibodies were conjugated with the fluorescent dye IRDye 800CW (Li-Cor; Lincoln, NE, USA). The investigators used singleplex, optimized NIR-LFAs to measure IL-6 from 0 to 200 pg/mL and developed duplex assays to simultaneously measure IL-6 from 0 to 100 pg/mL (0 to 4.5 pmol/L) and CRP from 50 to 2,500 ng/mL (0.4 to 20 nmol/L) on a single test strip. Assays were tested on 60 different spiked samples and compared to enzyme-linked immunosorbent assay (ELISA) results. The intensity ratios for unknown samples were compared to the calibration curve to determine analyte concentrations and samples were run in quadruplicate.

The choice of an inhibition-style assay rather than a sandwich-style assay avoided the complications due to a potential hook effect at high CRP concentrations. With this approach, free CRP present in the sample inhibited binding of the dye-conjugated antibody to CRP striped on the membrane. As the concentration of CRP in the sample increases, the signal directly decreases. The NIR-LFAs detected IL-6 in a 10% plasma matrix with a limit of detection of 4 pg/mL (182 fmol/L). The duplex NIR-LFAs quantitatively measured IL-6 and CRP concentrations simultaneously. The values strongly correlated to ELISA measurements, with linear regression R2 values of 0.9825 and 0.9711 for IL-6 and CRP, respectively.

The authors concluded that NIR-LFAs exhibit quantitative measurement at pg/mL concentrations owing to a high signal-to-background ratio and robust detection antibody clearance through the test strip. Moreover, NIR-LFAs are able to detect molecules present at vastly different concentrations in multiplex format and compare favorably to ELISAs. LFAs with direct NIR detection may be a valuable tool for biomarker evaluation in the point-of-care setting. The study was published on January 30, 2013, in the journal Clinical Chemistry.

Related Links:
SRI International
Li-Cor



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.